CN110836974B - Application of FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit - Google Patents
Application of FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit Download PDFInfo
- Publication number
- CN110836974B CN110836974B CN201911083968.4A CN201911083968A CN110836974B CN 110836974 B CN110836974 B CN 110836974B CN 201911083968 A CN201911083968 A CN 201911083968A CN 110836974 B CN110836974 B CN 110836974B
- Authority
- CN
- China
- Prior art keywords
- flt3lg
- lung adenocarcinoma
- protein
- reagent
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
Abstract
The invention belongs to the technical field of biomedicine, and particularly discloses application of FLT3LG protein in preparation of a lung adenocarcinoma postoperative prognosis evaluation reagent or kit. The invention takes FLT3LG protein as a marker, detects lung adenocarcinoma tissue specimens by an immunohistochemical method, and judges the prognosis of a lung adenocarcinoma patient; FLT3LG protein is highly expressed in lung adenocarcinoma and is low expressed in paracarcinoma tissues; the expression level of FLT3LG protein in lung adenocarcinoma is related to the survival time of patients; the prognosis of the high-expression patient is poor, and the survival time is short. The expression level of the FLT3LG protein is related to the overall survival time of the lung adenocarcinoma patients and the tumor-free survival time of the patients, and the patients with high FLT3LG protein expression have relapse or metastasis early; the FLT3LG protein is used as a lung adenocarcinoma diagnosis and prognosis marker, and has wide application prospect and great social benefit.
Description
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to application of FLT3LG protein in preparation of a lung adenocarcinoma postoperative prognostic evaluation reagent or kit.
Background
Lung cancer is the most serious malignant tumor with the highest morbidity and cancer mortality worldwide, and seriously threatens the life health of human beings. In China, lung cancer has replaced liver cancer to become the highest-mortality malignant tumor at present, and accounts for 22.7 percent of the total death number of all malignant tumors, and the morbidity and mortality of the lung cancer still rapidly increase. According to statistics, about 40 ten thousand cases of lung cancer die each year in China, and the lung cancer becomes the malignant tumor with the highest morbidity and mortality in China. Despite recent advances in lung cancer diagnosis and treatment with advances in technology, the survival rate of lung cancer patients is still not ideal, only about 20%, for 5 years after treatment. The 5-year survival rate of lung cancer patients is not ideal, and is related to the fact that most lung cancer patients are in a local advanced stage or have metastasis at the time of diagnosis, so that the lung cancer patients lose timely intervention and treatment opportunities, and the prognosis condition of the lung cancer patients is seriously influenced. Therefore, the key to improve the prognosis survival rate of the lung cancer patients lies in early diagnosis and intervention treatment.
Lung adenocarcinoma is a type of lung cancer, which is a malignant tumor derived from glandular epithelium in lung tissue, and has various growth patterns including acinar, papilla, bronchioloalveolar or parenchymal growth, and the like. Lung adenocarcinoma accounts for about 40% of primary lung tumors, and the proportion thereof is increasing year by year, and it is more likely to occur in women and those who do not smoke. Lung adenocarcinoma is common in peripheral lung cancer, has no obvious symptoms in the early stage, and is still easily ignored when the symptoms of the respiratory system such as cough, hemoptysis, chest pain and the like are developed along with the disease. In the late stage, symptoms are related to invasion and metastasis of tumors, such as stimulation of pleural effusion, pain caused by metastasis to bone joints, corresponding symptoms caused by metastasis to the skull and the like.
Currently, diagnostic treatment strategies for lung adenocarcinoma range from traditional TNM staging to treatment regimens, to individualized targeted therapies based on patient differential genotyping. Such as: the tyrosine kinase inhibitor has good curative effect on lung adenocarcinoma patients with Epidermal Growth Factor Receptor (EGFR) gene mutation, and the mutation is especially common in lung adenocarcinoma patients of Asian and female. Among them, deletion of exon 19 or point mutation of L858R 21 of EGFR gene is a more common therapeutically effective type of mutation. Therefore, the detection of the EGFR gene can effectively predict the targeted therapeutic effect of the lung adenocarcinoma. In addition, mutations in Anaplastic Lymphoma Kinase (ALK) gene rearrangement, ROS sarcoma carcinogen-receptor tyrosine kinase (ROS1), were better in young non-smoking patients. The mutation rate of the polypeptide is lower than that of EGFR, but the polypeptide is also used as an essential index for molecular biological detection of patients with lung adenocarcinoma, and directly guides the treatment scheme of the patients.
However, the treatment of patients with early and middle stage lung adenocarcinoma still takes operation as the main part, and the prediction of postoperative survival of the patients has no good index. At present, tumor serum markers Cyfta21-1, CEA, CA125 and the like which are clinically and frequently used for lung cancer cannot well reflect the postoperative prognosis of a lung cancer patient, and the detection of oncogenes (such as Ras, myc, erb-b2 and the like) or cancer suppressor genes (p53, RB and the like) cannot specifically evaluate the lung adenocarcinoma prognosis. Therefore, there is a need to further explore related proteins that can predict the prognosis of lung adenocarcinoma patients after surgery.
FLT3LG (Fms-related tyrosine kinase 3ligand) Fms-related tyrosine kinase 3ligand is a protein encoded by the FLT3LG gene in humans. It is structurally homologous to Stem Cell Factor (SCF) and colony stimulating factor 1 (CSF-1). In synergy with other growth factors, FLT3LG stimulates the proliferation and differentiation of various blood cell progenitors. For example, it is the major growth factor that stimulates the growth of dendritic cells. In addition, the kit has a certain effect on prognosis evaluation of malignant tumors such as osteosarcoma and the like, but the lung cancer prognosis evaluation is not reported in documents.
Disclosure of Invention
The invention provides an application of FLT3LG protein in preparing a lung adenocarcinoma postoperative prognosis evaluation reagent or a kit, wherein the expression level of FLT3LG protein in lung adenocarcinoma is related to the survival time of a patient and the tumor-free survival time of the patient, the survival time of the patient with high FLT3LG protein expression is short, and the patient has relapse or metastasis early, and the FLT3LG protein is used as a lung adenocarcinoma diagnosis and prognosis marker, so that the kit has wide application prospect and great social benefit.
The invention provides an application of FLT3LG protein in preparation of a lung adenocarcinoma postoperative prognosis evaluation reagent or a kit.
Preferably, in the above application, the FLT3LG protein is used as a molecular marker, a FLT3LG primary antibody, a HRP labeled secondary antibody and an immunohistochemical test reagent are used for analyzing the expression level of the FLT3LG protein in lung adenocarcinoma tissues, and the prognosis survival period of the patient after operation is evaluated according to the expression level of the FLT3LG protein.
Preferably, in the above application, the primary FLT3LG antibody refers to rabbit anti-human FLT3LG monoclonal antibody, and the HRP-labeled secondary antibody refers to horseradish peroxidase-labeled mouse anti-rabbit IgG antibody.
Preferably, in the above application, the immunohistochemical reagent comprises xylene, ethanol, and 3% H 2 O 2 Solution, 1% BSA blocking solution, DAB chromogenic reagent and hematoxylin.
Preferably, in the above application, the FLT3LG protein expression level is detected in a biological sample, wherein the biological sample is lung adenocarcinoma tissue embedded in paraffin after formalin fixation.
Preferably, in the above application, the method for detecting the relative expression level of the FLT3LG protein in lung adenocarcinoma tissue is as follows:
a) fixing the specimen with formaldehyde, dehydrating with alcohol, clearing xylene, embedding with paraffin and slicing;
b) baking at 50 deg.C for 2 hr, slicing, dewaxing with xylene, and gradient alcohol hydrating;
c) volume fraction 3% H 2 O 2 Incubating for 10min, washing with distilled water and PBS buffer solution for 2 times, each time for 5min
d) Performing antigen retrieval with 0.01M citric acid buffer solution, and heating in microwave oven at 98 deg.C for 10 min;
e) after cooling to room temperature, PBS buffer was added 2 times for 5min each
f) After 1h blocking with volume fraction 1% BSA, primary antibody incubations: rabbit anti-human FLT3LG monoclonal antibody was added and the mixture was refrigerated overnight (at least 12h) at 4 ℃.
g) Re-warming at room temperature for 20min, and buffering with PBS for 5min for 2 times;
h) and (3) secondary antibody incubation: adding corresponding horseradish peroxidase-labeled mouse anti-rabbit IgG antibody, and incubating at 37 ℃ for 30 min;
i) PBS buffer for 5min for 2 times; developing the DAB kit for 1-10 min;
j) fully washing with tap water to stop dyeing; counterstaining with hematoxylin for 10 s;
k) gradient alcohol dehydration, xylene transparency, sealing and air drying.
l) observing results under a microscope, randomly selecting 10 areas, and grading;
m) is divided into 0 to 3 points according to the staining intensity, 1 to 4 points according to the percentage of the positive cells, the multiplication of the staining index and the positive cells is the staining index, the high expression of FLT3LG protein is divided into more than or equal to 4 points, and the low expression is divided into less than 4 points.
Preferably, in the above application, the total survival time and the tumor-free survival time after the operation of the lung adenocarcinoma patient are shortened by the increase of the expression level of FLT3LG protein.
Compared with the prior art, the application of the FLT3LG protein in preparing the reagent or the kit for the prognosis evaluation after lung adenocarcinoma surgery has the following beneficial effects:
the invention aims to provide a novel application of FLT3LG protein, in particular to an application in preparing a reagent or a kit for prognosis evaluation of lung adenocarcinoma.
The invention is widely and deeply researched, and firstly discovers that the relative expression quantity of the FLT3LG protein in lung adenocarcinoma tissues is detected by an immunohistochemical method, so that the prognostic recurrence or metastasis and the postoperative survival period of a lung adenocarcinoma patient can be judged, and based on the correlation between the relative expression quantity of the FLT3LG protein and the lung adenocarcinoma, the detection of the expression quantity by taking the protein as a molecular marker can be used for guiding the prognostic judgment of the lung adenocarcinoma.
The discovery of the relevance of the FLT3LG protein and the lung adenocarcinoma provides a new method for predicting the recurrence and metastasis of lung adenocarcinoma prognosis and the postoperative survival period, has important value for judging the prognosis of lung adenocarcinoma patients, and when the immunohistochemical score is more than or equal to 4, the lung adenocarcinoma patients are easy to relapse or metastasize after operation, and the survival time is short.
The invention utilizes immunohistochemical technology to detect the relative expression quantity of the FLT3LG protein in lung adenocarcinoma tissues, statistically analyzes clinical pathological data of patients and combines follow-up information to determine the relevance of the relative expression quantity of the FLT3LG protein to the prognosis of lung adenocarcinoma patients after operation. The FLT3LG protein can be used as a protein molecular marker for judging the prognosis of a patient with lung adenocarcinoma, and has certain effects on postoperative adjuvant therapy and disease monitoring.
Drawings
FIG. 1 shows positive results of immunohistochemical staining of FLT3LG protein in lung adenocarcinoma tissue;
FIG. 2 shows the result of negative immunohistochemical staining of FLT3LG protein in lung adenocarcinoma tissue;
FIG. 3 shows positive results of immunohistochemical staining of FLT3LG protein in paracancer lung tissue;
FIG. 4 shows the negative result of the immunohistochemical staining of FLT3LG protein in the paracancer lung tissue;
FIG. 5 is a graph of FLT3LG protein expression versus overall survival in lung adenocarcinoma patients;
FIG. 6 is a graph of FLT3LG protein expression versus tumor-free survival in patients with lung adenocarcinoma;
FIG. 7 is a KM-Plotter database analyzing the relationship between FLT3LG gene expression and prognosis in lung adenocarcinoma;
FIG. 8 is a KM-Plotter database analyzing the relationship between FLT3LG gene expression and prognosis in squamous cell lung carcinoma.
Detailed Description
The invention is described in detail below with reference to the figures and the specific embodiments, but the invention should not be construed as being limited thereto. The experimental procedures in the following examples were carried out in a conventional manner unless otherwise specified, and materials, reagents and the like used in the following examples were commercially available unless otherwise specified.
The invention provides application of FLT3LG protein in preparation of a lung adenocarcinoma postoperative prognosis evaluation kit. The term "lung adenocarcinoma surgery" refers to the lung adenocarcinoma patients who have undergone surgical treatment, and the term "prognosis evaluation" refers to the prediction of survival time and recurrence and metastasis of the patients after tumor surgical resection. The amino acid sequence of the FLT3LG protein is shown as SEQ ID NO.1, and the nucleotide sequence of the encoded FLT3LG protein is shown as SEQ ID NO. 1.
To demonstrate the effect of the present invention, we conducted a related study:
first, research method
1. Patient collection: 132 lung cancer surgery patients were collected from 1 month 2010 to 2014 12 months sienna transportation university first subsidiary hospital and were confirmed as lung adenocarcinoma after the surgery. Of these, 69 men and 63 women ranged in age from 32 to 80 years (median age 60.5 years). In the experiment, the non-small cell lung cancer is staged according to the pathological description of the postoperative patient and the 8 th lung cancer TNM stage of the International anticancer Union (UICC) in 2017. Since stage IV patients do not benefit from surgery, the specimens collected are stage I, stage II, and stage III patients, and no stage IV patients.
2. Patient enrollment conditions: (1) the selected patients are not treated by any anti-tumor treatment methods such as chemotherapy, radiotherapy, immunotherapy and the like before operation; (2) the pathological examination of the patient after the operation proves that the lung adenocarcinoma is formed; (3) the patient had no other tumors and had no history of other tumors; (4) the patient's surgical procedure is radical lung cancer (radical lung cancer resection); (5) the patients and their families agree to take the samples of lung adenocarcinoma resection specimen after the operation.
3. Follow-up: overall Survival (OS) refers to the time from the date of lung cancer surgery to the death or loss of visit of the patient. The last follow-up date is 12 months in 2018. Survival for all patients ranged from 1-95 months, with a median survival of 43.5 months.
4. Preparation of immunohistochemical experimental liquid
4.1 preparation of gradient alcohol solution: the volume fractions of 70%, 80%, 85%, 90% and 95% alcohol are diluted with absolute ethanol and distilled water.
4.2 preparation of PBS buffer solution: sodium chloride 12g, sodium dihydrogen phosphate anhydrous (Na) 2 HPO 4 )1.725g, dipotassium hydrogen phosphate anhydrous (K) 2 HPO 4 )0.3g of potassium chloride and 0.3g of distilled water are used for preparing 1200ml of the solution, and the pH value is adjusted to 7.2;
4.3 preparation of citric acid buffer solution/antigen retrieval solution (0.01M): citric acid A solution: 2.1g of citric acid is fully dissolved in 100ml of distillation water; trisodium citrate solution B: 2.9g of trisodium citrate is dissolved in 100ml of distillation water; sequentially extracting 9ml of citric acid A solution and 41ml of trisodium citrate B solution, adding 450ml of distilled water, mixing to obtain 500ml of total amount, preparing into citric acid buffer solution with pH value of 6.0, and reserving for use.
4.4 mounting agent: 0.5ml of PBS buffer solution in 4.2 is uniformly mixed with the same volume of glycerol for use, and the mixture is required to be prepared for use.
5. Preparation of specimen and immunohistochemical reaction (a method for detecting the relative expression of FLT3LG protein in lung adenocarcinoma tissue)
5.1 specimen fixation: all isolated lung adenocarcinoma specimens were fixed within 3h, using 40% formaldehyde by volume fraction (commercially available formaldehyde reagents are available).
5.2, preparing a wax block: fresh lung adenocarcinoma specimens (about 1.0 cm. times.1.0 cm. times.0.2 cm in size) from the operating room were fixed with 40% volume fraction formaldehyde at room temperature around 25 ℃ for at least 12 h. Then dehydrated with alcohol and xylene transparent (85% ethanol 5min, 90% ethanol 5min, 95% ethanol 5min, anhydrous ethanol 5min, first xylene soaking 10min, second xylene soaking 10min) and paraffin embedding.
5.3 slicing preparation: cutting into pieces with thickness of 4-6 μm with manual paraffin slicer, spreading in water at 40-45 deg.C, and naturally flattening slightly-wrinkled paraffin tape by water tension and water temperature. Then carefully placed into the slides, then all slides were placed in a 40 ℃ dry box overnight (at least 12h), then placed in a 65 ℃ oven for 1.5h, and finally placed in a 37 ℃ incubator overnight (at least 12h), and the resulting paraffin sections were stored at ambient temperature and taken up for use.
5.4 immunohistochemical Experimental procedures
a) Baking slices: placing the paraffin sections into an oven to be baked for 2 hours at 50 ℃;
b) dewaxing: paraffin sections were placed in xylene for 20min (first time) and xylene for 20min (second time);
c) hydration: conventional hydration, i.e. 10min of absolute ethyl alcohol, 5min of 95% alcohol, 5min of 80% alcohol and 5min of 70% alcohol;
d) and (3) incubation: volume fraction 3% H 2 O 2 Incubating for 10min at room temperature to eliminate the activity of endogenous peroxidase in tumor tissues;
e) and (3) flushing: washing with distilled water, soaking in PBS buffer solution twice for 5min each time;
f) antigen retrieval: placing the slices into 0.01M citric acid antigen repairing buffer solution, heating in a microwave oven at 98 deg.C for 10min, taking out, and standing at room temperature for 30 min;
g) washing: washing with PBS buffer solution twice, each for 5 min;
h) after 1h blocking with volume fraction 1% BSA, primary antibody incubations: adding rabbit anti-human FLT3LG monoclonal antibody (primary antibody, Abcame company, cat # ab52648, 1:100 dilution) with corresponding concentration, placing into a wet box, placing gauze and a small amount of water into the box, and placing into a refrigerator at 4 deg.C overnight (at least 12 h);
i) rewarming: taking out the product the next day, standing at room temperature, and rewarming for 20 min;
j) washing: washing with PBS buffer solution twice, each for 5 min;
k) and (3) secondary antibody incubation: adding corresponding horse radish peroxidase-labeled mouse anti-rabbit IgG antibody (secondary antibody, Boaosen, cat # bs-0295M-HRP, 1:500 dilution), and incubating at 37 deg.C for 30 min;
l) rinsing: washing with PBS buffer solution twice for 5min each time;
m) color development: performing color development by using a DAB kit (comprising solution A and solution B), namely adding 1 drop of the DAB kit solution A and 1 drop of the DAB kit solution B into 1ml of distilled water under the condition of keeping out of the sun, mixing and then dropping into slices;
n) observation: after development for 30 seconds, the staining was observed under a microscope at intervals of about 10 seconds, and the development time was increased if necessary. The dyeing time is 1-10 min.
o) stop staining: fully washing with tap water;
p) counterstaining: counterstaining with hematoxylin for 10 s;
q) dehydration: dehydrating with 80% ethanol for 5min, 95% ethanol for 5min, and 100% ethanol for 10 min;
r) transparent: xylene 10min (first), xylene 10min (second);
s) sealing sheet: dripping a sealing tablet into the mixture for sealing, and putting the mixture into an air box for air drying;
t) observation: the sections were observed under a microscope, and 10 regions of each section tissue were randomly selected for observation and scored.
u) judging the result:
in this set of experiments, positive results of immunohistochemical staining of tumor cell FLT3LG were shown by the appearance of specific tan particles in the cytoplasm of the cells, see fig. 1; a negative result of the histochemical staining is represented by almost no specific staining in the cytoplasm of the cells, see fig. 2. In each specimen, 10 high-power fields were randomly selected under 400 × field for each index, and the percentage of positive cells was calculated. In positive staining, the colorless score was 0; light yellow is rated 1; the deep yellow color was rated 2 points; the brown-yellow color was rated 3. The non-positive cells are specified to be 0 point; the percentage of positive cells is 1 point < 25%; the percentage of the positive cells is 2 minutes between 25 percent and 50 percent; the percentage of the positive cells accounting for 50-75 percent is 3 minutes; the percentage of positive cells greater than 75% was 4 points. Multiplying the color score by the percentage score of the positive cells to obtain a staining index, wherein the staining index is more than or equal to 4, the high expression of the FLT3LG protein in the tumor tissue is judged, and the staining index is less than 4, the low expression of the FLT3LG protein in the tumor tissue is judged.
6. Analysis by statistical methods
Statistical analysis was performed using SPSS 20.0 software. In the experimental results, the counting data were counted using the chi-square test method. Survival analysis adopts a Kaplan-Meier method, the difference significance is tested by using Log-Rank, and a survival curve is drawn by GraphPad Prism 5 software. And analyzing the risk factors of the lung adenocarcinoma patient prognosis by using a single-factor and multi-factor Cox regression model. P <0.05 was considered statistically significant.
Second, research results
Comparison of expression levels of FLT3LG protein in lung adenocarcinoma tissue and paracancer lung tissue
FIG. 1 shows positive results of immunohistochemical staining of FLT3LG protein in lung adenocarcinoma tissue; FIG. 2 shows the result of negative immunohistochemical staining of FLT3LG protein in lung adenocarcinoma tissue; FIG. 3 shows the positive result of the immunohistochemical staining of the protein FLT3LG in the paracancer lung tissue, and FIG. 4 shows the negative result of the immunohistochemical staining of the protein FLT3LG in the paracancer lung tissue. In 132 lung adenocarcinoma tissues, the FLT3LG protein was highly expressed in 70 cases (53%), and lowly expressed in 62 cases (47%); in 82 cases of paracancer lung tissues, FLT3LG protein was highly expressed in 25 cases (37.8%) and low in 57 cases (62.2%). As can be seen from table 1, FLT3LG protein expression in lung adenocarcinoma tissue was significantly higher than in paracancerous lung tissue (p < 0.05).
TABLE 1 expression of FLT3LG protein in lung adenocarcinoma tissue and paracancer lung tissue
2. Relationship between FLT3LG protein expression and clinical pathological data in lung adenocarcinoma tissue
Table 2 shows the relationship between FLT3LG protein expression and clinical pathological data and factors, and the expression of FLT3LG protein in lung adenocarcinoma tissue is obviously related to whether lymph node metastasis occurs and TNM stage of tumor (P <0.05), but is not related to sex, age, smoking, tumor differentiation degree, tumor size, tumor position, tumor type and the like (P > 0.05).
TABLE 2 relationship between FLT3LG protein expression and clinical pathological data and factors
Correlation of FLT3LG expression with prognosis in patients with lung adenocarcinoma
The Kaplan-Meier method is used for carrying out survival analysis on FLT3LG high-expression and low-expression groups in lung adenocarcinoma, the total survival time (OS) of FLT3LG high-expression patients (FLT3LG +) low-expression patients (FLT3LG-) is obviously shortened (figure 5), and the difference of the two is statistically significant (P <0.001) in a Log rank test. The relationship between the expression of FLT3LG and the recurrence and metastasis of patients with lung adenocarcinoma is analyzed, and the patients with FLT3LG and high-expression lung adenocarcinoma (FLT3LG +) are found to be low-expression patients (FLT3LG-), the tumor-free survival period (DFS) is obviously shortened (figure 6), the difference is significant (P is 0.001), and the patients with FLT3LG and low expression are more likely to have recurrence and metastasis.
4. Single-factor and multi-factor Cox regression analysis of influence factors on overall survival time of lung adenocarcinoma patients
As shown in Table 3, in the single-factor analysis, the tumor size, the lymph node metastasis condition, the TNM stage and the FLT3LG protein expression condition have statistical significance (p is less than 0.05) on the overall survival prognosis of the lung adenocarcinoma patients, and the factors are all the factors influencing the overall survival of the lung adenocarcinoma patients. Table 4 shows that the expression of FLT3LG protein, the size of tumor, and lymph node metastasis are independent risk factors for the overall prognosis survival of lung adenocarcinoma (p <0.05) by selecting the tumor size, the lymph node metastasis, and the FLT3LG protein expression at the same time (since the TNM stage is determined by the tumor size and the lymph node metastasis, this factor is eliminated in the multifactorial analysis).
TABLE 3 Cox Single factor analysis Total Life time influencing factors
TABLE 4 Cox multifactor analysis Total Life time independent influence factors
5. Single-factor and multi-factor Cox regression analysis of influence factors on tumor-free survival of lung adenocarcinoma patients
As shown in Table 5, in the single-factor analysis, the tumor size, the lymph node metastasis, the TNM stage and the FLT3LG protein expression have statistical significance (p is less than 0.05) on the tumor-free survival of the lung adenocarcinoma patients, and all the factors are the tumor-free survival influencing factors of the lung adenocarcinoma patients. Table 6 shows that the tumor size, lymph node metastasis and FLT3LG protein expression were selected simultaneously, and the FLT3LG protein expression, tumor size and lymph node metastasis were found to be independent risk factors for the tumor-free survival of lung adenocarcinoma (p <0.05) using Cox multifactorial survival analysis.
TABLE 5 Cox Single factor analysis tumor-free survival influencing factors
TABLE 6 Cox multifactor analysis Total Life time independent influence factors
KM-Plotter database validation results
Data analysis was performed by KM-Plotter database (http:// kmplot. com/analysis /), and in public database, further validated the relationship of FLT3LG gene expression to lung adenocarcinoma. The results are shown in FIGS. 7 and 8. Among them, 720 lung adenocarcinoma population analyzed the relationship between FLT3LG gene expression and patient prognosis, it can be seen that the survival time of 388 patients with lower expression of 332 patients with high expression of FLT3LG gene was shortened, the difference was statistically significant (P <0.001), and in this database, the relative risk coefficient of FLT3LG high expression was 1.6 (95% confidence interval was 1.27-2.02). While analyzing the relationship between FLT3LG gene expression and prognosis in 524 lung squamous cell carcinomas, 251 lung squamous cell carcinomas with high expression and 273 lung squamous cell carcinomas with low expression of FLT3LG showed no significant difference in prognosis (P ═ 0.23). The expression level of the FLT3LG gene can be used for pertinently predicting the postoperative prognostic survival time of the lung adenocarcinoma patient, and is consistent with the prediction of the postoperative prognostic survival time of the lung adenocarcinoma patient by the FLT3LG protein expression of our experimental results.
While preferred embodiments of the present invention have been described, additional variations and modifications in those embodiments may occur to those skilled in the art once they learn of the basic inventive concepts. Therefore, it is intended that the appended claims be interpreted as including preferred embodiments and all such alterations and modifications as fall within the scope of the invention.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Sequence listing
<110> first subsidiary Hospital of medical college of Western-Ann transportation university
Application of <120> FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit
<160> 2
<170> PatentIn version 3.3
<210> 1
<211> 235
<212> PRT
<213> Artificial sequence
<400> 1
Met Thr Val Leu Ala Pro Ala Trp Ser Pro Thr Thr Tyr Leu Leu Leu
1 5 10 15
Leu Leu Leu Leu Ser Ser Gly Leu Ser Gly Thr Gln Asp Cys Ser Phe
20 25 30
Gln His Ser Pro Ile Ser Ser Asp Phe Ala Val Lys Ile Arg Glu Leu
35 40 45
Ser Asp Tyr Leu Leu Gln Asp Tyr Pro Val Thr Val Ala Ser Asn Leu
50 55 60
Gln Asp Glu Glu Leu Cys Gly Gly Leu Trp Arg Leu Val Leu Ala Gln
65 70 75 80
Arg Trp Met Glu Arg Leu Lys Thr Val Ala Gly Ser Lys Met Gln Gly
85 90 95
Leu Leu Glu Arg Val Asn Thr Glu Ile His Phe Val Thr Lys Cys Ala
100 105 110
Phe Gln Pro Pro Pro Ser Cys Leu Arg Phe Val Gln Thr Asn Ile Ser
115 120 125
Arg Leu Leu Gln Glu Thr Ser Glu Gln Leu Val Ala Leu Lys Pro Trp
130 135 140
Ile Thr Arg Gln Asn Phe Ser Arg Cys Leu Glu Leu Gln Cys Gln Pro
145 150 155 160
Asp Ser Ser Thr Leu Pro Pro Pro Trp Ser Pro Arg Pro Leu Glu Ala
165 170 175
Thr Ala Pro Thr Ala Pro Gln Pro Pro Leu Leu Leu Leu Leu Leu Leu
180 185 190
Pro Val Gly Leu Leu Leu Leu Ala Ala Ala Trp Cys Leu His Trp Gln
195 200 205
Arg Thr Arg Arg Arg Thr Pro Arg Pro Gly Glu Gln Val Pro Pro Val
210 215 220
Pro Ser Pro Gln Asp Leu Leu Leu Val Glu His
225 230 235
<210> 2
<211> 708
<212> DNA
<213> Artificial sequence
<400> 2
atgacagtgc tggcgccagc ctggagccca acaacctatc tcctcctgct gctgctgctg 60
agctcgggac tcagtgggac ccaggactgc tccttccaac acagccccat ctcctccgac 120
ttcgctgtca aaatccgtga gctgtctgac tacctgcttc aagattaccc agtcaccgtg 180
gcctccaacc tgcaggacga ggagctctgc gggggcctct ggcggctggt cctggcacag 240
cgctggatgg agcggctcaa gactgtcgct gggtccaaga tgcaaggctt gctggagcgc 300
gtgaacacgg agatacactt tgtcaccaaa tgtgcctttc agcccccccc cagctgtctt 360
cgcttcgtcc agaccaacat ctcccgcctc ctgcaggaga cctccgagca gctggtggcg 420
ctgaagccct ggatcactcg ccagaacttc tcccggtgcc tggagctgca gtgtcagccc 480
gactcctcaa ccctgccacc cccatggagt ccccggcccc tggaggccac agccccgaca 540
gccccgcagc cccctctgct cctcctactg ctgctgcccg tgggcctcct gctgctggcc 600
gctgcctggt gcctgcactg gcagaggacg cggcggagga caccccgccc tggggagcag 660
gtgccccccg tccccagtcc ccaggacctg ctgcttgtgg agcactga 708
Claims (6)
1. An application of a reagent for detecting the expression quantity of FLT3LG protein in lung adenocarcinoma tissues in preparing a lung adenocarcinoma postoperative prognosis evaluation reagent or a kit.
2. The application of the reagent for detecting the expression level of FLT3LG protein in lung adenocarcinoma tissue in the preparation of a lung adenocarcinoma postoperative prognosis evaluation reagent or kit according to claim 1, wherein FLT3LG protein is used as a molecular marker, FLT3LG primary antibody, HRP labeled secondary antibody and an immunohistochemical experiment reagent are used for analyzing the expression level of FLT3LG protein in lung adenocarcinoma tissue, and the postoperative prognosis survival period of the patient is evaluated according to the expression level of FLT3LG protein.
3. The application of the reagent for detecting the expression level of FLT3LG protein in lung adenocarcinoma tissues in preparing lung adenocarcinoma postoperative prognosis evaluation reagents or kits according to claim 2, wherein the FLT3LG primary antibody is rabbit anti-human FLT3LG monoclonal antibody, and the HRP-labeled secondary antibody is horseradish peroxidase-labeled mouse anti-rabbit IgG antibody.
4. The use of the reagent for detecting the expression level of FLT3LG protein in lung adenocarcinoma tissue according to claim 2 in the preparation of a reagent or a kit for the postoperative prognostic evaluation of lung adenocarcinoma, wherein the immunohistochemical test reagent comprises xylene, ethanol, 3% H 2 O 2 Solution, 1% BSA blocking solution, DAB chromogenic reagent and hematoxylin.
5. The use of the reagent for detecting the expression level of FLT3LG protein in lung adenocarcinoma tissue in the preparation of a lung adenocarcinoma postoperative prognosis evaluation reagent or kit according to claim 2, wherein the reagent is characterized in that the expression level of FLT3LG protein is detected in a biological sample, and the biological sample is formalin-fixed paraffin-embedded lung adenocarcinoma tissue.
6. The use of the reagent for detecting the expression level of FLT3LG protein in lung adenocarcinoma tissue for preparing a lung adenocarcinoma postoperative prognosis evaluation reagent or kit according to claim 1, wherein the increase of the expression level of FLT3LG protein shortens the postoperative overall survival and tumor-free survival of lung adenocarcinoma patients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911083968.4A CN110836974B (en) | 2019-11-07 | 2019-11-07 | Application of FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911083968.4A CN110836974B (en) | 2019-11-07 | 2019-11-07 | Application of FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110836974A CN110836974A (en) | 2020-02-25 |
| CN110836974B true CN110836974B (en) | 2022-09-09 |
Family
ID=69574650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911083968.4A Active CN110836974B (en) | 2019-11-07 | 2019-11-07 | Application of FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110836974B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111781358A (en) * | 2020-07-13 | 2020-10-16 | 张瑜 | XAB2 protein as ovarian cancer prognosis and/or prediction platinum drug resistance marker |
| CN113652487B (en) * | 2021-09-14 | 2022-04-05 | 山东大学第二医院 | Application of human C11orf86mRNA in evaluating lung adenocarcinoma patient prognosis and detection kit |
| CN116574808A (en) * | 2023-03-31 | 2023-08-11 | 广东医科大学 | Lung cancer biomarker, and detection system and kit thereof |
| CN116656814A (en) * | 2023-03-31 | 2023-08-29 | 广东医科大学 | Biomarker for prognosis evaluation of lung adenocarcinoma, detection system and kit thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240056629A (en) * | 2014-09-28 | 2024-04-30 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | Modulation of stimulatory and non-stimulatory myeloid cells |
-
2019
- 2019-11-07 CN CN201911083968.4A patent/CN110836974B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma:prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases;Akihiko Yoshizawa等;《Modern Pathology》;20110121;第24卷;653-664 * |
| Quantitative Computed Tomographic Descriptors Associate Tumor Shape Complexity and Intratumor Heterogeneity with Prognosis in Lung Adenocarcinoma;Olya Grove等;《PLOS ONE》;20150304;1-14 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110836974A (en) | 2020-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110836974B (en) | Application of FLT3LG protein in preparation of lung adenocarcinoma postoperative prognosis evaluation reagent or kit | |
| US10365283B2 (en) | Activated HER3 as a marker for predicting therapeutic efficacy | |
| Decenzo et al. | Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma | |
| Suzuki et al. | Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma | |
| Moretti et al. | β-adrenoceptors are upregulated in human melanoma and their activation releases pro-tumorigenic cytokines and metalloproteases in melanoma cell lines | |
| Garcia et al. | A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study | |
| Shaoyan et al. | Downregulation of EIF4A2 in non–small-cell lung cancer associates with poor prognosis | |
| Hou et al. | High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers | |
| Jiang et al. | High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients | |
| CN111679072B (en) | Application of KDM6B protein in breast cancer prognosis evaluation kit and diagnosis kit | |
| CN108369234B (en) | Methods of identifying individuals to be treated by chemotherapy based on marker molecules and related uses | |
| Mauro et al. | Estrogen receptor β and epidermal growth factor receptor as early-stage prognostic biomarkers of non-small cell lung cancer | |
| Asioli et al. | Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer | |
| Matsumoto et al. | HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial) | |
| Takenaka et al. | Serum Level of Osteopontin as a Prognostic Factor in Patients Who Underwent Surgical Resection for Non–Small-Cell Lung Cancer | |
| CN103502470A (en) | Use of the olfactomedin-4 protein (olfm4) in colorectal cancer diagnosis | |
| CN109975549A (en) | Purposes of the tumour source IgG in diagnosis of pancreatic cancer or prognosis | |
| CN111218509A (en) | Novel diagnostic marker PPEF1 for breast cancer and application thereof | |
| JP4628365B2 (en) | Immunohistochemical method | |
| CN102183655B (en) | New molecular marker CUEDC2 (CUE Domain Containing 2) protein for prognosis judgement in endocrine therapy of breast cancer | |
| Riener et al. | RETRACTED: The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study | |
| CN103969452B (en) | The classification diagnosis kit of BAY 43-9006 personalized treatment liver cancer | |
| CN111893182A (en) | Application of citrate synthetase in preparation of kit for diagnosing and evaluating prostate cancer | |
| Sato et al. | Expression of HER2/neu does not correlate with survival in soft tissue sarcoma | |
| Li et al. | CRTC2 and PROM1 expression in non-small cell lung cancer: analysis by Western blot and immunohistochemistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |